A Phase 3 interventional study of Travoprost 0.004% PQ ophthalmic solution and Timolol, 0.5% or 0.25% ophthalmic solution in Pediatric Glaucoma, Elevated IOP in Pediatric Patients and Ocular Hypertension in Pediatric Patients, sponsored by Alcon Research. Completed. Open to participants aged 2 Months to 17 Years. Per ClinicalTrials.gov, last updated 2015-07-23.
Sponsored by Alcon Research (part of Alcon) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the intraocular pressure (IOP)-lowering efficacy of Travoprost 0.004% POLYQUAD (PQ) ophthalmic solution compared to Timolol ophthalmic solution (0.5% or 0.25%) in pediatric glaucoma patients.
37 studies on the registry are indexed under Hydrophthalmos; 3 are open to participants now.
This study's enrollment of 184 is above the median of 37 across 29 interventional studies indexed under Hydrophthalmos.
Browse Hydrophthalmos studies →Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Travoprost 0.004% PQ ophthalmic solution, 1 drop administered in each eye in the evening with travoprost vehicle administered once daily in the morning for 3 months
Drug: Travoprost 0.004% PQ ophthalmic solution · Drug: Travoprost Vehicle
Timolol, 0.5% or 0.25% ophthalmic solution, 1 drop administered in each eye twice daily (once in the morning and once in the evening) for 3 months
Drug: Timolol, 0.5% or 0.25% ophthalmic solution
Patients 2 months to \< 3 years of age received 0.25%
Inactive ingredients used to maintain masking
Mean Change From Baseline in IOP at Month 3
IOP (fluid pressure inside the eye) was assessed using a calibrated tonometer and measured in millimeters of mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye from each participant was chosen as the study eye and only the study eye was used for analysis.
Time frame: Baseline (Day 0), Month 3
Participants were recruited from 38 investigational centers in the United States, Germany, Singapore, United Kingdom, Taiwan, Philippines, Spain, Saudi Arabia, Colombia, France, Portugal, Belgium, Poland, Romania, Puerto Rico, and Mexico.
| Milestone | Travoprost | Timolol |
|---|---|---|
| Started | 77 | 75 |
| Completed | 71 | 74 |
| Not completed | 6 | 1 |
| Withdrew: Treatment failure | 5 | 1 |
| Withdrew: Inadequate iop control | 1 | 0 |
IOP (fluid pressure inside the eye) was assessed using a calibrated tonometer and measured in millimeters of mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye from each participant was chosen as the study eye and only the study eye was used for analysis.
| mmHg | Travoprost | Timolol |
|---|---|---|
| Mean Change From Baseline in IOP at Month 3 | -5.4 ± 0.98 | -5.3 ± 0.93 |
Collected over Adverse events (AEs) were collected for the duration of the study (05 Sep 2012 - 25 Mar 2014). This analysis group includes all enrolled participants.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pre-Treatment | — | 0/184 (0%) | 1/184 (0.5%) |
| Travoprost | — | 0/77 (0%) | 22/77 (28.6%) |
| Timolol | — | 2/75 (2.7%) | 6/75 (8%) |
| Event | Pre-Treatment | Travoprost | Timolol |
|---|---|---|---|
| Keratitis bacterialInfections and infestations | 0/184 | 0/77 | 1/75 |
| PneumoniaInfections and infestations | 0/184 | 0/77 | 1/75 |
| Viral infectionInfections and infestations | 0/184 | 0/77 | 1/75 |
| Event | Pre-Treatment | Travoprost | Timolol |
|---|---|---|---|
| Ocular hyperaemiaEye disorders | 0/184 | 15/77 | 3/75 |
| Growth of eyelashesEye disorders | 0/184 | 5/77 | 0/75 |
| HeadacheNervous system disorders | 1/184 | 5/77 | 2/75 |
| Conjunctival hyperaemiaEye disorders | 0/184 | 4/77 | 1/75 |
This analysis population includes all participants who received study drug and completed at least 1 scheduled on-therapy visit.
| Age, Customized(participants) | Travoprost | Timolol | Total |
|---|---|---|---|
| 2 months to <3 years | 10 | 6 | 16 |
| 3 to <12 years | 40 | 39 | 79 |
| 12 to <18 years | 27 | 30 | 57 |
| Sex: Female, Male(Participants) | Travoprost | Timolol | Total |
|---|---|---|---|
| Female | 40 | 40 | 80 |
| Male | 37 | 35 | 72 |
| Intraocular Pressure(mmHg) | Travoprost | Timolol | Total |
|---|---|---|---|
| Mean | 24.7 ± 4.62 | 24.2 ± 4.01 | 24.4 ± 4.32 |
No study locations are listed for this record.
The record gives a start of Sep 2012, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Travoprost